Relevant bibliographies by topics / Prophylactic vaccine

Academic literature on the topic 'Prophylactic vaccine'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prophylactic vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prophylactic vaccine"

1

Mandic, Aljosa. "Prophylactic HPV vaccines." Archive of Oncology 17, no. 3-4 (2009): 68–71. http://dx.doi.org/10.2298/aoo0904068m.

Full text
Abstract:
Human papillomavirus (HPV) is one of the most common sexually transmitted diseases worldwide. Cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis are HPV associated diseases. Prophylactic HPV vaccines are composed of HPV L1 capsid protein that self-assemble into virus-like particles (VLPs) when expressed in recombinant systems. Two types of prophylactic vaccines are designed as a bivalent vaccine to protect against high-risk HPV types 16 and 18 and a quadrivalent vaccine designed to protect against HPV 16 and 18, and low-risk, genital wart-causing HPV 6 and 11. Proof-of-principle trials have suggested that intramuscular injections of VLPs result in strong adaptive immune responses that are capable of neutralizing subsequent natural infections. Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results with nearly 100% efficacy in preventing the development of persistent infections and cervical precancerous lesions in vaccinated individuals.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhdanov, K. V., K. Kasyanenko, O. V. Mal'cev, N. I. L'vov, D. A. Lioznov, I. I. Lapikov, and K. S. Ivanov. "Evaluation of Seasonal Inactivated Influenza Vaccines Prophylactic Efficacy." Epidemiology and Vaccinal Prevention 21, no. 5 (November 19, 2022): 98–106. http://dx.doi.org/10.31631/2073-3046-2022-21-5-98-106.

Full text
Abstract:
Relevance. Seasonal flu vaccination is still the most effective way to protect against flu viruses and help to reduce the burden of flu illnesses. Another possible benefit is the impact of yearly vaccines on severity of breakthrough infection. In this regard, the issue of choosing safe vaccine with high immunogenicity becomes relevant.Aims. To evaluate the prophylactic efficacy of inactivated seasonal flu vaccines (quadrivalent subunit vaccine with adjuvant and trivalent vaccine) and reactogenicity of quadrivalent vaccine.Materials and methods. 491 cases were included in our study: 152 cases received adjuvanted quadrivalent subunit flu vaccine «Grippol Quadrivalent», 118 cases received trivalent inactivated flu vaccine and 221 cases who have received no vaccinations during 2018–2019 epidemic season.Results. inactivated vaccines showed high prophylactic efficacy in preventing seasonal influenza. Incidence of influenza and other viral respiratory disease cases was lowest in «Grippol Quadrivalent» group. Breakthrough influenza cases in individuals vaccinated with inactivated vaccine were predominantly mild, no severe cases were reported. The early post-vaccination period in «Grippol Quadrivalent» group showed no variation in adverse events with other vaccines.Conclusion. Adjuvanted quadrivalent subunit flu vaccine was the most efficacious in preventing influenza in 2018–2019 epidemic season.
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, YeLei. "The advancement of the HPV vaccine program: focus on adolescents." Highlights in Science, Engineering and Technology 19 (November 17, 2022): 231–35. http://dx.doi.org/10.54097/hset.v19i.2859.

Full text
Abstract:
HPV is currently a major hazard to human health. Whether the HPV vaccination program will be effectively promoted in the future depends on the awareness and attention of adolescents and children to the vaccine, and whether their parents are willing to let adolescents and children to be vaccinated.However,a number of issues have arisen in the process. The main thrust of this writing is to examine and review the relevant literature,including the background knowledge of prophylactic HPV vaccine,personal acceptance by adolescents and parental acceptance, and some of the potential social issues.It summarizes the existing types of prophylactic HPV vaccines and the corresponding disease prevention, the principle and background of prophylactic HPV vaccines.Some of the potential social issues, such as conspiracy theorists' rumors about the prophylactic HPV vaccine, people's prejudices about the vaccine, and the price of the vaccine are described.In the end, the future application of prophylactic HPV vaccinesis prospected.
APA, Harvard, Vancouver, ISO, and other styles
4

Czerwińska, Ewa, Marita Nittner-Marszalska, Janusz Zaryczański, Grzegorz Gąszczyk, Agnieszka Mastalerz-Migas, and Leszek Szenborn. "Influenza and Other Prophylactic Vaccination Coverage in Polish Adult Patients Undergoing Allergen Immunotherapy—A Survey Study among Patients and Physicians." Vaccines 10, no. 4 (April 8, 2022): 576. http://dx.doi.org/10.3390/vaccines10040576.

Full text
Abstract:
Vaccines against infectious diseases may raise safety concerns in patients undergoing allergen immunotherapy (AIT). The objective of our study was to investigate influenza vaccine and other selected prophylactic vaccines coverage in patients treated with AIT and the attitude of physicians towards vaccinations in this group of patients. We conducted a questionnaire-based study among patients undergoing AIT and physicians. The patients’ survey evaluated influenza and other prophylactic vaccines coverage. The physicians’ survey assessed their experience and opinions on prophylactic vaccinations during AIT. In total, 176 patients (aged 18–79 years) and 120 doctors filled the questionnaires. Patients were assigned to two groups—inhaled allergens group (n = 101) and insect venoms group (n = 68). The number of patients who received any dose (36% and 45%, p = 0.26), as well as two or more doses (17% and 22%, p = 0.43) of influenza vaccine was comparable between two groups. However, in both groups there was a significant (p < 0.0001) decrease in influenza vaccine uptake after the beginning of AIT. Patients from the inhaled allergens group declared a higher tetanus vaccine rate (41% vs. 19%, p = 0.004). The groups did not differ in the pneumococcal and tick-borne encephalitis vaccination coverage. A majority of doctors believe that prophylactic vaccinations in patients undergoing AIT are safe and effective (96% and 94%, respectively); however, as many as 87% of them identify with the need to create clear recommendations regarding vaccinating patients undergoing AIT. Prophylactic vaccine coverage is not satisfactory among Polish adult patients undergoing AIT. Polish doctors are convinced of the validity of prophylactic vaccinations during AIT.
APA, Harvard, Vancouver, ISO, and other styles
5

Toft, Lars, Martin Tolstrup, Merete Storgaard, Lars Østergaard, and Ole S. Søgaard. "Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives." Sexual Health 11, no. 6 (2014): 511. http://dx.doi.org/10.1071/sh14015.

Full text
Abstract:
Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some countries have implemented specific HPV vaccination recommendations for HIV-positive populations. To specifically recommend prophylactic HPV vaccination in people with HIV, the vaccines must be safe and immunogenic in immunosuppressed people at a high risk of HPV infection. This review aims to summarise the current knowledge from published HPV vaccine trials in HIV-infected populations, to compile scheduled and ongoing HPV vaccine trials with HIV-positive study populations and to extrapolate the relevant knowledge about HPV vaccine efficacy in HIV-negative populations to an HIV context. Methods: The databases PubMed, Scopus and ClinicalTrials.gov were searched for peer-reviewed articles and scheduled or ongoing clinical HPV vaccine trials enrolling HIV-positive persons. Results: Current data indicate that prophylactic HPV vaccines are safe and immunogenic in different HIV-positive populations (children, female adolescents, adults). Increased immunogenicity has been reported in persons on antiretroviral therapy compared with antiretroviral-naïve persons, whereas no clear association has been found between CD4+ cell count at immunisation and vaccine response. Several scheduled and ongoing HPV vaccine trials aim to determine vaccine efficacy against disease endpoints in HIV-infected study populations. Conclusion: Prophylactic HPV vaccination appears safe, immunogenic and, by extrapolation, likely to reduce HPV-associated cancer development among persons with HIV infection.
APA, Harvard, Vancouver, ISO, and other styles
6

KAWANA, Kei. "Human papillomavirus prophylactic vaccine." Uirusu 62, no. 1 (2012): 79–86. http://dx.doi.org/10.2222/jsv.62.79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lowy, Douglas R., and John T. Schiller. "Papillomaviruses: prophylactic vaccine prospects." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1423, no. 1 (January 1999): M1—M8. http://dx.doi.org/10.1016/s0304-419x(98)00037-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Paavonen, Jorma, and Matti Lehtinen. "Prophylactic Human Papillomavirus Vaccine." Women's Health 2, no. 1 (January 2006): 5–6. http://dx.doi.org/10.2217/17455057.2.1.5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ko, Eun-Ju, and Marjorie Robert-Guroff. "Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination." Viruses 12, no. 1 (December 24, 2019): 24. http://dx.doi.org/10.3390/v12010024.

Full text
Abstract:
Dendritic cells (DCs) are involved in human and simian immunodeficiency virus (HIV and SIV) pathogenesis but also play a critical role in orchestrating innate and adaptive vaccine-specific immune responses. Effective HIV/SIV vaccines require strong antigen-specific CD4 T cell responses, cytotoxic activity of CD8 T cells, and neutralizing/non-neutralizing antibody production at mucosal and systemic sites. To develop a protective HIV/SIV vaccine, vaccine regimens including DCs themselves, protein, DNA, mRNA, virus vectors, and various combinations have been evaluated in different animal and human models. Recent studies have shown that DCs enhanced prophylactic HIV/SIV vaccine efficacy by producing pro-inflammatory cytokines, improving T cell responses, and recruiting effector cells to target tissues. DCs are also targets for therapeutic HIV/SIV vaccines due to their ability to reverse latency, present antigen, and augment T and B cell immunity. Here, we review the complex interactions of DCs over the course of HIV/SIV prophylactic and therapeutic immunizations, providing new insights into development of advanced DC-targeted HIV/SIV vaccines.
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Yike, Xiaofen Huang, Zhigang Zhang, Shaowei Li, Jun Zhang, Ningshao Xia, and Qinjian Zhao. "Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation." Viruses 12, no. 1 (January 16, 2020): 109. http://dx.doi.org/10.3390/v12010109.

Full text
Abstract:
Hepatitis E virus (HEV) infection causes sporadic outbreaks of acute hepatitis worldwide. HEV was previously considered to be restricted to resource-limited countries with poor sanitary conditions, but increasing evidence implies that HEV is also a public health problem in developed countries and regions. Fortunately, several vaccine candidates based on virus-like particles (VLPs) have progressed into the clinical development stage, and one of them has been approved in China. This review provides an overview of the current HEV vaccine pipeline and future development with the emphasis on defining the critical quality attributes for the well-characterized vaccines. The presence of clinically relevant epitopes on the VLP surface is critical for eliciting functional antibodies against HEV infection, which is the key to the mechanism of action of the prophylactic vaccines against viral infections. Therefore, the epitope-specific immunochemical assays based on monoclonal antibodies (mAbs) for HEV vaccine antigen are critical methods in the toolbox for epitope characterization and for in vitro potency assessment. Moreover, serological evaluation methods after immunization are also discussed as biomarkers for clinical performance. The vaccine efficacy surrogate assays are critical in the preclinical and clinical stages of VLP-based vaccine development.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prophylactic vaccine"

1

Engels, Robert Klaus. "Towards developing a prophylactic vaccine against the pre-erythrocytic stage of 'P. vivax' malaria using 'P. cynomolgi' as a model." Thesis, University of Oxford, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Fan [Verfasser], and Frank [Akademischer Betreuer] Rösl. "Re-engineering a Nanoparticle Human Papillomavirus Prophylactic Vaccine Antigen Based on the Minor Capsid Protein L2 / Fan Yang ; Betreuer: Frank Rösl." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/121816798X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schumann, Alexandra [Verfasser], Michael Akademischer Betreuer] Roggendorf, Monika [Akademischer Betreuer] [Lindemann, and Bertram [Akademischer Betreuer] Opalka. "Hepatitis B virus specific adoptive immune transfer in living liver donation and characterization of a prophylactic/therapeutic vaccine against Hepadnaviral infection / Alexandra Schumann. Gutachter: Michael Roggendorf ; Bertram Opalka. Betreuer: Michael Roggendorf ; Monika Lindemann." Duisburg, 2014. http://d-nb.info/1058329529/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hepburn, Drobnjak Helena Maria [Verfasser]. "Long term cellular immune response to prophylactic human papillomavirus (HPV) vaccines / Helena Maria Hepburn Drobnjak." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2012. http://d-nb.info/1030382581/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Desai, Kamal. "Phase III clinical trials of prophylactic HIV-1 vaccines, validation of efficacy measures and sample size." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ57961.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wilson, John Edward. "A comparison of alternate mucosal routes of prophylactic immunisation using a mouse model of Helicobacter infection /." View thesis, 2001. http://library.uws.edu.au/adt-NUWS/public/adt-NUWS20030704.133959/index.html.

Full text
Abstract:
Thesis (M.Sc.) (Honours) -- University of Western Sydney, Hawkesbury, 2001.
A thesis submitted for the degree of Master of Science (Honours), Centre for Farming Systems Research, University of Western Sydney, Hawkesbury, 2001. Bibliography : leaves 142-162.
APA, Harvard, Vancouver, ISO, and other styles
7

Payette, Paul J. "The use of DNA for the development of novel prophylactic and therapeutic vaccines against the hepatitis B virus." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ66183.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Xueer [Verfasser], and Martin [Akademischer Betreuer] Müller. "Development of prophylactic and therapeutic combined vaccines against human papillomaviruses (HPV) using a multimerized thioredoxin (Trx) scaffold / Xueer Zhao ; Betreuer: Martin Müller." Heidelberg : Universitätsbibliothek Heidelberg, 2020. http://d-nb.info/1213097118/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bazan, Silvia Boschi. "Expressão da proteína L1 do capsídio de HPV-16 em leveduras metilotróficas." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/46/46131/tde-18102007-171459/.

Full text
Abstract:
Papilomavírus humanos (HPVs) são vírus de DNA que infectam células epiteliais, podendo ser responsáveis pelo aparecimento de lesões benignas e malignas. Dentre os mais de 120 tipos identificados, o HPV -16 constitui o principal agente etiológico do câncer cervical, que é uma das maiores causas de morte por câncer em mulheres no mundo. Sendo assim, infecções associadas ao HPV devem ser prevenidas por vacinas indutoras de resposta imune vírus-específicas. A proteína L1 do capsídio viral é capaz de arranjar-se em partículas morfologicamente e antigenicamente semelhantes ao vírus, denominadas \"virus-like particles\" (VLPs), que induzem altos títulos de anticorpos neutralizantes. Neste trabalho, foram clonados os genes L1 selvagem e otimizado de HPV -16 em vetores de expressão de leveduras metilotróficas como Hansenula polymorpha e Pichia pastoris. Foi observada uma expressão consistente da proteína recombinante apenas em P. pastoris, com o gene L1 otimizado. Foram realizadas diversas tentativas de purificação da proteína heteróloga, empregando técnicas de cromatografia e ultracentrifugação em gradiente descontínuo de sacarose. A correta montagem das VLPs foi confirmada por microscopia eletrônica. Problemas de agregação, heterogeneidade e adsorção a superfícies apresentados pela proteína L1 foram resolvidos após utilização de surfactante não-iônico e de um procedimento de desmontagem e remontagem das partículas, gerando preparações mais homogêneas. Ensaios de hemaglutinação e inibição da hemaglutinação comprovaram a apresentação de epítopos conformacionais na superfície das VLPs. Este trabalho demonstrou pela primeira vez a expressão da proteína L1 de HPV -16 em P. pastoris, visando ao desenvolvimento de uma vacina profilática de baixo custo para o sistema público de saúde.
Human papillomaviruses (HPVs) are DNA viruses that infect epithelial cells and can cause both benign and malignant lesions. From over 120 types catalogued so far, HPV-16 is the main etiologic agent of cervical cancer, which is the one of the most common causes of cancer deaths among women worldwide. Thus, HPV -associated infections might be prevented by vaccine inducing virus-specific immune responses. The L1 major capsid protein can self assemble into virus-like particles (VLPs), which are morphologically and antigenically indistinguishable from native viruses and induce high titers of neutralizing antibodies. In this work, we have cloned wild-type and codon-optimized L1 genes from HPV-16 in expression vectors of the methylotrophic yeasts Hansenula polymorpha and Pichia pastoris. Consistent L1 expression was only observed in P. pastoris transformed with the construction containing the codon-optimized gene. Many attempts to purify the heterologous protein were made, including chromatography and ultracentrifugation in sucrose density gradients. The correct assembly of VLPs was confirmed by electron microscopy. Some problems presented by recombinant L1 like aggregation, surface adsorption and heterogeneity were solved by using non-ionic surfactants and a procedure of disassembly and reassembly of the particles. Hemagglutination and hemagglutination inhibition assays corroborated the display of surface conformational epitopes by VLPs. This work showed for the first time the expression of the HPV-16 L1 protein in P. pastoris, aiming the development of a prophylactic vaccine free of charge for the public health system in Brazil.
APA, Harvard, Vancouver, ISO, and other styles
10

"Investigation of Tumor Frame Shift Antigens for Prophylactic Cancer Vaccine, Cancer Detection and Tumorigenicity." Doctoral diss., 2012. http://hdl.handle.net/2286/R.I.15925.

Full text
Abstract:
abstract: Cancer is one of the most serious global diseases. We have focused on cancer immunoprevention. My thesis projects include developing a prophylactic primary and metastatic cancer vaccines, early cancer detection and investigation of genes involved in tumor development. These studies were focused on frame-shift (FS) antigens. The FS antigens are generated by genomic mutations or abnormal RNA processing, which cause a portion of a normal protein to be translated out of frame. The concept of the prophylactic cancer vaccine is to develop a general cancer vaccine that could prevent healthy people from developing different types of cancer. We have discovered a set of cancer specific FS antigens. One of the FS candidates, structural maintenance of chromosomes protein 1A (SMC1A) FS, could start to accumulate at early stages of tumor and be specifically exposed to the immune system by tumor cells. Prophylactic immunization with SMC1A-FS could significantly inhibit primary tumor development in different murine tumor models and also has the potential to inhibit tumor metastasis. The SMC1A-FS transcript was detected in the plasma of the 4T1/BALB/c mouse tumor model. The tumor size was correlated with the transcript ratio of the SMC1A-FS verses the WT in plasma, which could be measured by regular RT-PCR. This unique cancer biomarker has a practical potential for a large population cancer screen, as well as clinical tumor monitoring. With a set of mimotope peptides, antibodies against SMC1A-FS peptide were detected in different cancer patients, including breast cancer, pancreas cancer and lung cancer with a 53.8%, 56.5% and 12.5% positive rate respectively. This suggested that the FS antibody could be a biomarker for early cancer detection. The characterization of SMC1A suggested that: First, the deficiency of the SMC1A is common in different tumors and able to promote tumor initiation and development; second, the FS truncated protein may have nucleolus function in normal cells. Mis-control of this protein may promote tumor development. In summary, we developed a systematic general cancer prevention strategy through the variety immunological and molecular methods. The results gathered suggest the SMC1A-FS may be useful for the detection and prevention of cancer.
Dissertation/Thesis
Ph.D. Molecular and Cellular Biology 2012
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Prophylactic vaccine"

1

Gray, Lynn. The worldwide market for prophylactic and therapeutic vaccines. Norwalk, CT: Business Communications Co., 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel, and M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.

Full text
Abstract:
While the HIV/AIDS pandemic continues, the overall incidence of HIV infections has fallen through use of antiretroviral therapy (ART) and multiple prevention modalities. To achieve a durable end to the pandemic and avoid the requirement for daily antiretroviral medication over a lifetime, a safe and effective prophylactic vaccine remains essential. This chapter reviews current advances in prophylactic and therapeutic HIV-1 vaccine strategies and the challenges that lie ahead. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs) from infected individuals, the discovery of mechanisms of bnAb induction, and progress in understanding mechanisms of CD8 T-cell killing of HIV-infected cells and the structure of the HIV envelope trimer have opened new strategies for HIV vaccine design. On the therapeutic front, the persistence of HIV reservoirs remains a formidable obstacle to achieving sustained virological remission in HIV-infected individuals after ART is discontinued. Development of a new generation of immune-based therapeutic agents might contribute to a curative intervention. The chapter closes with an overview of ethical challenges in vaccine development and clinical testing.
APA, Harvard, Vancouver, ISO, and other styles
3

Burchell, Ann, and Eduardo Franco1. The impact of immunization on cancer control: the example of HPV vaccination. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199550173.003.0006.

Full text
Abstract:
Chapter 6 reviews briefly the role of infections as causal agents in cancer, describes anti-hepatitis B virus (HBV) immunization as the first cancer vaccine paradigm, and finally focuses on the latest paradigm of prophylactic vaccination against human papillomavirus (HPV) infection as the new front in cancer prevention.
APA, Harvard, Vancouver, ISO, and other styles
4

J, Zuckerman Arie, ed. Recent developments in prophylactic immunization. Dordrecht: Kluwer Academic Publishers, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Oldstone, Michael B. A. Viruses, Plagues, and History. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190056780.001.0001.

Full text
Abstract:
“Viruses, Plagues, & History” focuses on the effects of viral diseases on human history. Written by an eminent internationally respected virologist, it couples the fabric of history with major concepts developed in virology, immunology, vaccination, and accounts by people who first had, saw and acted at the times these events occurred. Much of the preventive and therapeutic progress (vaccines, antiviral drugs) has been made in the last 60 years. Many of those who played commanding roles in the fight to understand, control and eradicate viruses and viral diseases are (were) personally known to the author and several episodes described in this book reflect their input. The book records the amazing accomplishments that led to the control of lethal and disabling viral diseases caused by Smallpox, Yellow Fever, Measles, Polio, Hepatitis A, B and C, and HIV. These six success stories are contrasted with viral infections currently out of control—COVID-19, Ebola virus, Lassa Fever virus, Hantavirus, West Nile virus, and Zika. Influenza, under reasonable containment at present, but with the potential to revert to a world-wide pandemic similar to 1918–1919 where over 50 million people were killed. The new platforms to develop inhibitory and prophylactic vaccines to limit these and other viral diseases is contrasted to the anti-vaccine movement and the false prophets of autism.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Prophylactic vaccine"

1

Zhang, Jun, Qinjian Zhao, and Ningshao Xia. "Prophylactic Hepatitis E Vaccine." In Advances in Experimental Medicine and Biology, 223–46. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-024-0942-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Neurath, A. R. "Chemical synthesis of hepatitis B vaccine." In Recent Developments in Prophylactic Immunization, 210–42. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schiller, John T., and Douglas R. Lowy. "Developmental History of HPV Prophylactic Vaccines." In History of Vaccine Development, 265–84. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1339-5_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Krieg, Arthur M., and Heather L. Davis. "CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines." In Vaccine Adjuvants, 87–110. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59259-970-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Taylor, M. G., and G. Webbe. "Prospects for the development of a vaccine for schistosomiasis." In Recent Developments in Prophylactic Immunization, 289–312. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pushko, Peter, and Irina Tretyakova. "Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention." In Novel Technologies for Vaccine Development, 61–85. Vienna: Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1818-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Borovjagin, Anton V., Jorge G. Gomez-Gutierrez, Haval Shirwan, and Qiana L. Matthews. "Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines." In Novel Technologies for Vaccine Development, 203–71. Vienna: Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1818-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Smith, G. L. "Recombinant vaccinia virus vaccines." In Recent Developments in Prophylactic Immunization, 313–33. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ashworth, L. A. E., and A. Robinson. "Pertussis vaccines." In Recent Developments in Prophylactic Immunization, 1–19. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wall, R. A. "Meningoccal vaccines." In Recent Developments in Prophylactic Immunization, 20–46. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1067-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prophylactic vaccine"

1

Luhui, Shen, Hojoon Lee, Kathryn Sykes, and Stephen Albert Johnston. "Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-469.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miller, Michelle L., Jason Lohmueller, John R. McKolanis, Robert Schoen, and Olivera J. Finn. "Abstract 5643: TCRβ repertoire analysis from a prophylactic MUC1 cancer vaccine trial." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kimura, Takashi, John R. McKolanis, Robert E. Schoen, and Olivera J. Finn. "Abstract 5380: Prophylactic MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kharbikar, B. N., H. Kumar, R. Gope, N. Shriyan, D. Dave, and R. Srivastava. "Prophylactic (cold-chain independent) vaccination facilitated by microneedle patch of reinforced polymer with vaccine loaded silk nanoparticles." In Proceedings of the International Conference on Nanotechnology for Better Living. Singapore: Research Publishing Services, 2016. http://dx.doi.org/10.3850/978-981-09-7519-7nbl16-rps-219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lohmueller, Jason J., Shuji Sato, Wan Cheung Cheung, Isabel Chu, Lana Popova, Christopher A. Manning, Katherine Crosby, et al. "Abstract 2509: Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lupu, Vasile Valeriu, Ingrith Miron, Anamaria Ciubara, Valeriu Lupu, Iuliana Magdalena Starcea, Anca Adam Raileanu, Stefan Lucian Burlea, Alexandru Bogdan Ciubara, and Ancuta Lupu. "SARS COV 2 PANDEMIC - BETWEEN CAUTION AND PRUDENCE." In The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.3.

Full text
Abstract:
There is no doubt that a natural phenomenon of the magnitude of a pandemic requires a series of tough precautionary measures in order to limit the spread of the disease, to combat the manifestations of the disease by appropriate therapeutic means and to increase the resistance of the population through prophylactic immunisation, namely vaccination. At the same time, caution points out that not all precautionary measures achieve their aim, for at least two reasons: first, it is an extremely versatile micro-organism (like any virus) which can change its genetic configuration through mutations, thus retaining its main characteristics; contagiousness and pathogenicity; second, the preventive measures initially used: quarantine, mask and physical distancing, have proved to be totally outdated and ineffective in today's conditions (economic interdependence, population movement, overpopulation of the planet). The very vaccination on which so much hope was pinned has failed to stem the new pandemic waves (3 and 4), even in countries where the vaccine immunisation rate has exceeded 70%. The three major means of prevention are reviewed which, beyond the immense frustration they have produced in the population, have had a devastating socio-economic impact, and the results of forcible imposition have produced insignificant results. It has been demonstrated once again that the global approach to the pandemic is doomed to failure (witness the successive waves) and that precautionary measures are illusory. Thus, between precaution and prudence, prudence must prevail in order not to replace an existing evil with a greater evil. The only effective measures remain outbreak control with specific means (which epidemiologists know very well) and immunisation by vaccine.
APA, Harvard, Vancouver, ISO, and other styles
7

Luhui, Shen, Kathryn Sykes, and Stephen Albert Johnston. "Abstract 1570: Frameshift peptides as prophylactic cancer vaccines antigens." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1570.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jagu, Subhashini, Balasubramanyam Karanam, Ratish Gambhira, Sudha Chivukula, Revathi Chaganti, Douglas Lowy, John Schiller, and Richard Roden. "Abstract B93: Concatenated multitype L2 fusion proteins as prophylactic human papillomavirus vaccines." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b93.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Prophylactic vaccine"

1

Kotler, Moshe, Larry Hanson, and Shane Burgess. Replication Defective Cyprinid Herpes Virus-3 (CyHV-3) as a Combined Prophylactic Vaccine in Carps. United States Department of Agriculture, December 2010. http://dx.doi.org/10.32747/2010.7697104.bard.

Full text
Abstract:
Aquacultured koi and common carp fish (Cyprinus carpio) are intensively bred as ornamental and food fish in many countries worldwide. Hatcheries of carp and koi have recently suffered massive financial damages due to two viral diseases caused by the Cyprinid herpesvirus-3 (CyHV-3), previously designated as Carp Interstitial Nephritis and Gill Necrosis Virus (CNGV) and Koi herpesvirus (KHV), and by the Spring Viremia of Carp Virus (SVCV). CyHV-3 is a large dsDNA virus, which is infectious mostly to koi and common carp, while SVCV is a rhabdovirus with a relatively broad host range. Both viruses induce contagious disease with mortality rate up to 90%. Strategies for the control of viral infection in fish are of limited use. While efforts to prevent introduction of infectious agents into culture facilities are desirable, such exclusion strategies are far from fail-safe. Extensive vaccination methods that are useful for use in aquaculture facilities produce weak immunity, when used with proteins or inactivated viruses. Methods to overcome this obstacle are to vaccinate the fish with large amounts of antigen and/or use adjuvant and immune modulators over a long period. These techniques usually require individual handling of the fish. On the other hand, live attenuated virus is efficient and economical when used as an immersionvaccine. However, this technique poses certain environmental risks and thus may be difficult to license and scale up. Another option is a vaccine based on the replication defective virus (RDV) (pseudovirus), which can infect cells, but is unable to produce infectious particles. This vaccine may circumvent many of the problems related to attenuated-live vaccine (e.g., inadvertent infection and reversion to the virulent strain).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prophylactic vaccine' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography